/VYNT
VYNT Stock - Vyant Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$0.19+7.78%
+$0.01 (+7.78%) • Dec 29
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.41
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.21
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VYNT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.19 – $0.20
TARGET (TP)$0.22
STOP LOSS$0.18
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.56
52W High$1.58
52W Low$0.14
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $666,000 | $1.15M | $867,000 | $7.30M | $27.47M |
| Gross Profit | $-342,000 | $-699,000 | $-234,000 | $3.60M | $8.75M |
| Gross Margin | -51.4% | -60.9% | -27.0% | 49.3% | 31.8% |
| Operating Income | $-15,912,000 | $-15,706,000 | $-7,623,000 | $-2,713,000 | $-18,194,000 |
| Net Income | $-22,690,000 | $-46,095,000 | $-9,196,000 | $-6,708,000 | $-20,373,000 |
| Net Margin | -3406.9% | -4015.2% | -1060.7% | -91.8% | -74.2% |
| EPS | $-3.87 | $-10.19 | $-18.50 | $-17.40 | $-111.98 |
Company Overview
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
VYNTBeat Rate
33%
Last 6 quarters
Avg Surprise
-46.6%
EPS vs Estimate
Beats / Misses
2/2
2 met exactly
Latest EPS
$-0.72
Q1 2023
EPS Surprise History
Q2 21
No data
Q4 21
0.0%
$-0.75vs$-0.75
Q4 21
No data
Q1 22
+75.0%
$-0.20vs$-0.80
Q2 22
+6.3%
$-0.75vs$-0.80
Q3 22
0.0%
$-0.75vs$-0.75
Q4 22
-342.9%
$-0.62vs$-0.14
Q1 23
-18.0%
$-0.72vs$-0.61
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Mar 29, 2024 | — | — | — | — |
Q4 2023 | Dec 27, 2023 | — | — | — | — |
Q4 2023 | Oct 3, 2023 | — | — | — | — |
Q2 2023 | Jun 5, 2023 | — | — | — | — |
Q1 2023 | Mar 31, 2023 | $-0.61 | $-0.72 | -18.0% | ✗ MISS |
Q4 2022 | Nov 15, 2022 | $-0.14 | $-0.62 | -342.9% | ✗ MISS |
Q3 2022 | Aug 22, 2022 | $-0.75 | $-0.75 | 0.0% | = MET |
Q2 2022 | May 16, 2022 | $-0.80 | $-0.75 | +6.3% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.80 | $-0.20 | +75.0% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-4.29 | — | — |
Q4 2021 | Nov 11, 2021 | $-0.75 | $-0.75 | 0.0% | = MET |
Q2 2021 | May 17, 2021 | — | $-4.25 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-11.57 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.41 | — | — |
Q4 2020 | Nov 2, 2020 | — | $-4.70 | — | — |
Q3 2020 | Aug 13, 2020 | — | $-2.09 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-3.10 | — | — |
Q4 2019 | Nov 19, 2019 | — | $-0.70 | — | — |
Q3 2019 | Aug 19, 2019 | — | $4.85 | — | — |
Q2 2019 | May 20, 2019 | — | $-9.90 | — | — |
Latest News
Loading news...
Frequently Asked Questions about VYNT
What is VYNT's current stock price?
Vyant Bio, Inc. (VYNT) is currently trading at $0.19 per share. The stock has moved +7.78% today.
What is the analyst price target for VYNT?
No analyst price targets are currently available for this stock.
What sector is Vyant Bio, Inc. in?
Vyant Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VYNT's market cap?
Vyant Bio, Inc. has a market capitalization of N/A, making it a small-cap company.
Does VYNT pay dividends?
No, Vyant Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBLCM
Bellicum Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
CWBR
CohBar, Inc.
$0.41
Mkt Cap: $0.0B
CYTO
Altamira Therapeutics Ltd.
$0.30
Mkt Cap: $0.0B
IMPL
Impel Pharmaceuticals Inc.
$0.04
Mkt Cap: $0.0B
NBSE
NeuBase Therapeutics, Inc.
$0.38
Mkt Cap: $0.0B
NMTRQ
9 Meters Biopharma, Inc.
$0.00
Mkt Cap: $0.0B
NVIV
InVivo Therapeutics Holdings Corporation
$0.32
Mkt Cap: $0.0B
ONCT
Oncternal Therapeutics, Inc.
$0.53
Mkt Cap: $0.0B
SAVAW
Cassava Sciences, Inc. Warrant
$0.03
Mkt Cap: $0.0B
TMBR
Timber Pharmaceuticals, Inc.
$0.34
Mkt Cap: $0.0B
Explore stocks similar to VYNT for comparison